Format

Send to

Choose Destination
Health Qual Life Outcomes. 2019 Apr 29;17(1):74. doi: 10.1186/s12955-019-1136-7.

Psychometric analysis of the adult sickle cell quality of life measurement information system (ACSQ-Me) in a UK population.

Author information

1
School of Health Sciences, City, University of London, EC1V 0HB, London, UK.
2
East London NHS Foundation Trust, London, UK.
3
Barts Health NHS Trust, London, UK.
4
Homerton University Hospital NHS Foundation Trust, London, UK.
5
North Middlesex University Hospital, London, UK.
6
School of Health Sciences, City, University of London, EC1V 0HB, London, UK. kathleen.mulligan.1@city.ac.uk.
7
East London NHS Foundation Trust, London, UK. kathleen.mulligan.1@city.ac.uk.

Abstract

BACKGROUND:

The Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) has been shown to be a reliable and valid questionnaire measuring health-related quality of life (HRQoL) in the US sickle cell disease (SCD) population. The study objective was to test the validity and reliability of the ASCQ-Me for use in the UK.

METHODS:

The US ASCQ-Me, Hospital Anxiety and Depression Scale (HADS), self-reported symptoms, and Medical Outcome Survey Short Form 36 (SF-36) were administered to 173 patients with SCD. Clinical severity was assessed by the number of painful episodes indicated by hospital admissions.

RESULTS:

The results showed that the item banks of the UK ASCQ-Me had good internal consistency. Anxiety and depression were strongly correlated with the emotional, and social item banks of the UK ASCQ-Me, with moderate correlations between the UK ASCQ-Me item banks and SF-36 components suggesting convergent validity. A confirmatory factor analysis confirmed the conceptual framework of the scale as being the same as the US ASCQ-Me, indicating construct validity. Known groups validity was found, with the ASCQ-Me being able to differentiate by SCD severity groups.

CONCLUSION:

The analysis of the sample shows evidence of both validity and reliability of the ASCQ-Me for use in the UK SCD population.

KEYWORDS:

ASCQ-Me; Quality of life; SF-36; Sickle cell disease; Validity

PMID:
31036017
PMCID:
PMC6489218
DOI:
10.1186/s12955-019-1136-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center